NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Reports Second Quarter 2021 Operating Results

NanoString Releases Operating Results for Second Quarter of 2021

Intellia Therapeutics

Pacific Biosciences of California

Pinterest

Snap

With over 40 years of experience, Catherine Wood (Trades, Portfolio) founded ARK in 2014 to focus solely on disruptive innovation while adding new dimensions to research. Through an open approach that spans across sectors, market capitalizations and geographies, she believes ARK can identify large-scale investment opportunities in the public markets resulting from technological innovations centered around DNA sequencing, robotics, artificial intelligence, energy storage and blockchain technology.

5 Most Profitable Holdings of Catherine Wood's ARK

SEATTLE--(BUSINESS WIRE)--NanoString to report second quarter 2021 operating results and host conference call on Wednesday, August 4th.

NanoString to Release Second Quarter 2021 Operating Results and Host Conference Call on Wednesday, August 4, 2021

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® Stem Cell Characterization Panel for the analysis and optimization of stem cell lines used in the development of potential novel therapeutics. Recent breakthroughs in stem cell therapy, regenerative medicine, and CRISPR engineering have advanced the development of promising new treatments for debili

NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy

NanoString Technologies, Inc. is a genomics/proteomics-focused developer of advanced instruments and consumables for scientific and clinical research. NanoString's products consist of two commercially available product platforms, the nCounter Analysis System (launched in 2008) and the GeoMx Digital Spatial Profiler System ("DSP" launched in 2019).

NanoString: Compelling Upside For This Spatial Biology Instrument Developer

SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and the Parker Institute for Cancer Immunotherapy (PICI) announced today that they are collaborating on an expansive molecular characterization project for cellular therapies. The collaboration will define the characteristics that make a cell therapy effective, providing a standardized approach to developing CAR-T regimens tha

NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer

SEATTLE--(BUSINESS WIRE)--NanoString to webcast presentation from the Jefferies Virtual Healthcare conference.

NanoString to Webcast Presentation from the Jefferies Virtual Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString to webcast presentation from the UBS Global Healthcare Conference.

NanoString to Webcast Presentation from the UBS Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the Mouse Whole Transcriptome Atlas (WTA) for spatial analysis research using the GeoMx® Digital Spatial Profiler (DSP). This launch extends the GeoMx RNA portfolio, which combines the power of spatial biology and Next Generation Sequencing (NGS), to enable full transcriptome spatial RNA and high

NanoString's GeoMx Mouse Whole Transcriptome Atlas Expands Leadership in Spatial Genomics by Enabling Genome-Wide RNA Profiling

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q1 2021 Results - Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--NanoString Reports First Quarter 2021 Operating Results.

NanoString Technologies Releases Operating Results for First Quarter of 2021

Maravai LifeSciences Holdings

SmileDirectClub

Shockwave Medical

TG Therapeutics

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More

SEATTLE--(BUSINESS WIRE)--NanoString announced today that a peer-reviewed publication using the GeoMx® Digital Spatial Profiler is to be published in the journal Nature.

NanoString's Digital Spatial Profiling Platform Used to Create Foundational Dataset Revealing Insights into COVID-19

SEATTLE--(BUSINESS WIRE)--NanoString announces spatial biology highlights from the 2021 American Association of Cancer Research Conference.

NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research (AACR) Conference

SEATTLE--(BUSINESS WIRE)--NanoString announces date of First Quarter 2021 Operating Results and Conference Call on Monday, May 10, 2021

NanoString to Release First Quarter 2021 Operating Results and Host Conference Call on Monday, May 10, 2021

SEATTLE--(BUSINESS WIRE)--NanoString's GeoMx DSP reveals insights into COVID-19 in two new publications in Nature.

NanoString's GeoMx Digital Spatial Profiler Reveals Insights into COVID-19 in Two New Nature Publications

Arvinas Inc

Carvana

Plug Power

Redfin

Investors saw some downwards pressure on the indices to kick off Monday. But Q.ai's deep learning algorithms have crunched the numbers to bring you today's top short plays.

Top Stocks To Short Today Amid More Hedge Fund Problems

Murphy Oil

After the market sold off on the first anniversary of the bull market yesterday, investors saw renewed signs of recovery. Meanwhile, the deep learning algorithms at Q.ai have crunched the data to give you today's top shorts.

Top Shorts Today As Stocks Recover From Yesterday's Sell-Off

SEATTLE--(BUSINESS WIRE)-- #spatialbiology--NanoString enters spatial biology collaboration with Illumina Accelerator and Doloromics.

NanoString, Illumina Accelerator and Doloromics Announce GeoMx Digital Spatial Profiling Collaboration to Develop Novel Pain Therapeutics

Cardlytics

Laureate Education

TripAdvisor

United States Steel

Just as quickly as Nasdaq ﻿NDAQ﻿ hit correction territory twice in the last week, it saw sharp gains. Meanwhile, Q.ai's deep learning algorithms have brought you today's top shorts.

Top Stocks To Short Today As Nasdaq Pops Again

SEATTLE--(BUSINESS WIRE)--NanoString Technologies announced the appointment of two new board members, Dr. Dana Rollison and Janet George, effective March 8, 2021.

NanoString Appoints Dr. Dana Rollison and Janet George to Board of Directors

Cal-Maine Foods

Stitch Fix

The rotation into recovery continues as President Biden's stimulus proposal passed through the Senate. To make the most of this market, Q.ai's Artificial Intelligence has assessed each firm to find today's top short plays.

Top Stocks To Short Today As The Rotation Into Recovery Continues

NanoString Technologies, Inc. (NSTG) CEO Bradley Gray on Q4 2020 Results - Earnings Call Transcript

Shares of NanoString Technologies (NASDAQ:NSTG) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 15.87% year over year to ($0.53), which missed the estimate of ($0.49).

Recap: NanoString Technologies Q4 Earnings

SEATTLE--(BUSINESS WIRE)--NanoString releases Q4 and FY20 operating results.

News for NanoString Technologies Stock (NSTG)